RBN-2397, a PARP7 inhibitor, was found to be well tolerated and have preliminary antitumor activity as monotherapy in patients with advanced solid tumors, including head and neck squamous cell carcinoma, breast cancer, and squamous cell carcinoma of the lung.
When the fully human IgG4 monoclonal antibody SRK-181 was given as a monotherapy or in combination with anti–PD-1 or PD-L1 agents in patients with locally advanced or metastatic solid tumors, it was found to be generally well tolerated and to demonstrate early indications of efficacy.
An overview on novel treatment strategies in biliary tract cancers combining immune checkpoint inhibitors with various targeted agents.
Centering discussion on the TOPAZ-1 trial of chemotherapy in combination with durvalumab, panelists consider how this regimen has impacted clinical practice.
Before closing out their discussion on BRAF-mutated metastatic colorectal cancer, panelists consider other novel combination strategies in this setting.
Shared insight on the BREAKWATER trial, which combined encorafenib, cetuximab, and chemotherapy in patients with BRAF V600E–mutated metastatic colorectal cancer.
Durvalumab plus neoadjuvant chemotherapy followed by surgery and adjuvant single-agent durvalumab significantly improved event-free survival vs neoadjuvant chemotherapy and surgery alone in patients with resectable stage IIA-IIIB non–small cell lung cancer.
Key opinion leaders in the field of biliary tract cancers highlight mainstay systemic therapy regimens within the treatment paradigm.
A brief discussion on the continued role of liver transplant in biliary tract cancers and when it is appropriate to consider a patient for this procedure.
The advent of effective first-generation TKIs has allowed for improvements among patients with Philadelphia chromosome–positive disease, which is traditionally associated with a poor prognosis, as it generally does not respond to conventional chemotherapy options.
Expert perspectives on the BEACON CRC trial, which combined encorafenib, cetuximab, and binimetinib in patients with BRAF V600E–mutated metastatic colorectal cancer.
Following its discussion on trastuzumab deruxtecan and tucatinib therapy in HER2+ mCRC, the panel emphasizes the importance HER2 status identification in metastatic colorectal cancer.
Kelly K. Hunt, MD, FACS, FSSO, discusses technical considerations for axillary reverse mapping in breast cancer for the reduction or prevention of lymphedema.
Phillip J. Koo, MD, discusses ongoing areas of technological and therapeutic advancements within the prostate cancer landscape.
A comprehensive review of liver-directed therapies available to aid in the management of biliary tract cancers.
Enrollment has commenced for a phase 2 trial investigating the DNA-based interleukin-12 immunotherapy IMNN-001 in combination with bevacizumab and chemotherapy in patients with advanced ovarian cancer.
When treating patients with mantle cell lymphoma, early identification and appropriate frontline therapy remains critical, and therapies may vary for those 65 years and older compared with patients under the age of 65, with several additional factors also having a role in approaching treatment options for a new patient in the clinic.
For patients with acute myeloid leukemia, advances in targeting minimal residual disease represents the next wave of advances in the field and is necessary to cure this disease.
Switching their focus to tucatinib, expert panelists review data from the MOUNTAINEER study and define the role of tucatinib in managing HER2+ metastatic colorectal cancer.
Comprehensive insight on the adverse event profile of antibody drug conjugate therapy as it compares to other agents in HER2+ metastatic colorectal cancer management.
Jasmine Sukumar, MD, discusses the purpose of analyzing endocrine therapy use in HR-positive/HER2-positive patients, key data presented from the retrospective analysis at SABCS, and the need for improved understanding of clinical indications for endocrine therapy in this breast cancer subtype.
Expert hematologic oncologists discuss updates from the ASH 2022 Annual Meeting on emerging therapies for lower-risk MDS.
Following the ASH 2022 Annual Meeting, experts in hematologic oncology review updated data for luspatercept in lower-risk MDS.
Hematologic oncology experts give an overview of first- and second-line treatment options for lower-risk myelodysplastic syndromes.
Virginia Kaklamani, MD, discusses how racial disparities may affect patient outcomes and treatment expectations based on data from the RxPONDER trial in breast cancer.
Key opinion leaders review the advent of molecular testing in biliary tract cancers and consider its impact on informing treatment decisionmaking.
Focused conversation on the optimal workup and staging of biliary tract cancers within the current paradigm.
For patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-related adverse effect.
Phillip J. Koo, MD, highlights insights garnered from prostate cancer experts on topics such as radioligands and modern radiopharmaceuticals, which, along with artificial intelligence, have the potential to revolutionize the field.
Centering discussion on clinical trials and experience with trastuzumab deruxtecan, expert oncologists identify its value in the HER2+ treatment landscape.
